Novel therapies for multiple myeloma

被引：54

作者：

Hayashi, T

Hideshima, T

Anderson, KC

机构：

[1] Dana Farber Canc Inst, Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2003年 / 120卷 / 01期

关键词：

bone marrow microenvironment; thalidomide; proteasome inhibitor; NF-kappa B inhibitor;

D O I：

10.1046/j.1365-2141.2003.03929.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：10 / 17

页数：8

共 81 条

[11] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[12] Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines [J].

Damiano, JS ;

Cress, AE ;

Hazlehurst, LA ;

Shtil, AA ;

Dalton, WS .

BLOOD, 1999, 93 (05) :1658-1667

[13] Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma [J].

Dankbar, B ;

Padró, T ;

Leo, R ;

Feldmann, B ;

Kropff, M ;

Mesters, RM ;

Serve, H ;

Berdel, WE ;

Kienast, J .

BLOOD, 2000, 95 (08) :2630-2636

[14] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[15] High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment [J].

Davies, FE ;

Rollinson, SJ ;

Rawstron, AC ;

Roman, E ;

Richards, S ;

Drayson, M ;

Child, JA ;

Morgan, GJ .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (15) :2843-2851

[16] Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells [J].

Deaglio, S ;

Canella, D ;

Baj, G ;

Arnulfo, A ;

Waxman, S ;

Malavasi, F .

LEUKEMIA RESEARCH, 2001, 25 (03) :227-235

[17]

FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0

[18] Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [J].

Gabrilovich, DI ;

Chen, HL ;

Cunningham, HT ;

Meny, GM ;

Nadaf, S ;

Kavanaugh, D ;

Carbone, DP .

NATURE MEDICINE, 1996, 2 (10) :1096-1103

[19] PRODUCTION OF LYMPHOTOXIN, A BONE-RESORBING CYTOKINE, BY CULTURED HUMAN MYELOMA CELLS [J].

GARRETT, IR ;

DURIE, BGM ;

NEDWIN, GE ;

GILLESPIE, A ;

BRINGMAN, T ;

SABATINI, M ;

BERTOLINI, DR ;

MUNDY, GR .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (09) :526-532

[20] Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines [J].

GeorgiiHemming, P ;

Wiklund, HJ ;

Ljunggren, O ;

Nilsson, K .

BLOOD, 1996, 88 (06) :2250-2258

← 1 2 3 4 5 6 7 8 9 →